Effects of Boron Neutron Capture Therapy Using Borocaptate Sodium in Combination with a Tumor-selective Vasoactive Agent in Mice
- 1 March 1998
- journal article
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 89 (3) , 334-340
- https://doi.org/10.1111/j.1349-7006.1998.tb00567.x
Abstract
Boron neutron capture therapy (BNCT) destroys tumor cells by means of α particles and recoil protons emitted by 10B(n,α)7Li reaction. For BNCT to be effective, the tumor/normal tissue concentration ratio of 10B must be larger than 1.0, because neutron distribution is not selective. We examined the combination of 10B‐enriched borocaptate sodium (BSH) with flavone acetic acid (FAA) as a model compound which causes vascular collapse in squamous cell carcinoma in mice (SCCVII tumors) and would increase the tumor/normal tissue concentration ratio of 10B. FAA (200 mg/kg, i.p.) was injected, and 5 min later BSH (75 mg/kg, i.v.) was administered, followed 15 to 180 min later by irradiation with thermal neutrons. The 10B concentrations were measured by prompt gamma ray spectrometry. Without FAA, tumor 10B concentrations were less than or equal to normal tissue concentrations at all time intervals, except that the concentrations were 1.7‐ to 2.7‐fold greater in tumor than muscle at 15 and 180 min after injection of BSH. With FAA, 10B concentrations 2.1‐ to 6.9‐fold greater in tumor than in muscle were achieved at all intervals tested. For blood and skin, significant differential accumulations were found in tumors at 120 and 180 min. Tumor/liver ratios were less than 1 at all times. Cell survival was determined by in vivo/in vitro colony assay, and increasing radiosensitization correlated with increasing tumor 10B concentrations, whether or not they were achieved with FAA. Tumor control rates, determined at 180 days after BNCT, similarly appeared to depend only on 10B levels at the time of irradiation. Because 10B levels correlate with the radiation response of tissues, a therapeutic gain would be expected whenever the tumor levels exceed normal tissue levels, such as in tumors located in muscle irradiated at 15–180 min after FAA+BSH, or in those in skin irradiated at 120 and 180 min.Keywords
This publication has 17 references indexed in Scilit:
- Biodistribution of Boron Sulfhydryl for Boron Neutron Capture Therapy in Patients with Intracranial TumorsNeurosurgery, 1995
- Response of rat skin to boron neutron capture therapy with p-boronophenylalanine or borocaptate sodiumRadiotherapy and Oncology, 1994
- Flavone acetic acid as a modifier of endothelial cell functionInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Vascular collapse after flavone acetic acid: A possible mechanism of its anti-tumour actionEuropean Journal of Cancer and Clinical Oncology, 1989
- Flavone acetic acid—Preclinical and clinical activityEuropean Journal of Cancer and Clinical Oncology, 1989
- Radiosensitizing effect of misonidazole in combination with an inhibitor of glutathione synthesis in murine tumorsInternational Journal of Radiation Oncology*Biology*Physics, 1986
- Rapid and simple method for quantitative determination of non-protein sulphydryls in mouse liver by reversed-phase high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1985
- Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508International Journal of Radiation Oncology*Biology*Physics, 1984
- Microanalysis system of ppm-order 10B concentrations in tissue for neutron capture therapy by prompt gamma-ray spectrometryNuclear Instruments and Methods in Physics Research, 1983
- Penetration of Brain and Brain Tumor. VII. Tumor-Binding Sulfhydryl Boron CompoundsJournal of Medicinal Chemistry, 1967